Business Wire · NVCR · November 9, 2026

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

Get the app for more

Explore stock news, insights and company research.